국가: 영국
언어: 영어
출처: VMD (Veterinary Medicines Directorate)
Carprofen
Ceva Animal Health Ltd
QM01AE91
Carprofen
Tablet
POM-V - Prescription Only Medicine – Veterinarian
Dogs
Anti Inflammatory NSAID
Authorized
2008-06-04
Revised: May 2013 AN: 00442/2012 Page 1 of 5 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT CARPRODYL F 50 mg, tablets for dogs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains: Active ingredient: Carprofen ....................................................................................50 mg Excipients Yellow iron oxide (E172) ....................................................0.09375 mg For a full list of excipients, see section 6.1 3. PHARMACEUTICAL FORM Tablet. Circular, beige, scored tablets. The tablets can be divided into equal halves. 4. CLINICAL PARTICULARS 4.1 TARGET SPECIES Dogs. 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES Reduction of inflammation and pain caused by musculo-skeletal disorders and degenerative joint disease. As a follow up to parenteral analgesia in the management of post-operative pain. 4.3 CONTRAINDICATIONS Do not use in cats. Do not use in pregnant or lactating bitches. Do not use in cases of known hypersensitivity to the active substance or to any of the excipients of the product. Do not use in dogs suffering from cardiac, hepatic or renal disease, where there is a possibility of gastro-intestinal ulceration or bleeding, or where there is evidence of a blood dyscrasia. Do not use in pups less than 4 months of age. 4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES Revised: May 2013 AN: 00442/2012 Page 2 of 5 Refer to Sections 4.3 and 4.5. 4.5 SPECIAL PRECAUTIONS FOR USE SPECIAL PRECAUTIONS FOR USE IN ANIMALS Use in aged dogs may involve additional risk. If such a use cannot be avoided, dogs may require careful clinical management. Avoid use in any dehydrated, hypoproteinemic, hypovolaemic or hypotensive dog, as there is a potential risk of increased renal toxicity. NSAIDs can cause inhibition of phagocytosis and hence in the treatment of inflammatory conditions associated with bacterial infection, appropriate concurrent antimicrobial therapy should be instigated. Response to long term treatment should be monitored at regular 전체 문서 읽기